文献速递复苏、休克与脓毒症创伤与烧伤

速用冷沉淀产品在创伤/失血性休克及延长低血压复苏啮齿动物模型中提供持久器官保护

Immediate use cryoprecipitate products provide lasting organ protection in a rodent model of trauma/hemorrhagic shock and prolonged hypotensive resuscitation.
PubMed 文献 · J Trauma Acute Care Surg · 2023-06-14
一句话结论小鼠创伤/失血性休克模型中,冷沉淀、5日病原体灭活冷沉淀、冻干病原体灭活冷沉淀与新鲜冰冻血浆相当,提供持久器官保护。

研究在小鼠创伤/失血性休克模型(剖腹术后失血性休克,平均动脉压35 mmHg持续90分钟)中,比较乳酸林格液、新鲜冰冻血浆、冷沉淀、5日病原体灭活冷沉淀(5PRC)和冻干病原体灭活冷沉淀(LPRC)进行6小时低血压复苏(平均动脉压55-60 mmHg)的效果,随访72小时。结果显示冷沉淀、5PRC、LPRC和新鲜冰冻血浆达到目标平均动脉压所需复苏液量不到乳酸林格液的一半;72小时平均动脉压在冷沉淀、5PRC和新鲜冰冻血浆组显著高于乳酸林格液组。冷沉淀、5PRC和LPRC提供与新鲜冰冻血浆相当的持久肠道保护并增强syndecan免疫染色,而乳酸林格液组持续存在器官功能障碍。作者认为5PRC和LPRC的可用性将允许研究冷沉淀在严重创伤患者中的即时使用,冻干产品对院前、农村和战场使用有重要意义。

要点

  • 在小鼠创伤/失血性休克模型中,冷沉淀、5PRC、LPRC和新鲜冰冻血浆达到目标平均动脉压所需复苏液量不到乳酸林格液的一半。
  • 72小时平均动脉压在冷沉淀、5PRC和新鲜冰冻血浆组显著高于乳酸林格液组。
  • 冷沉淀、5PRC和LPRC提供与新鲜冰冻血浆相当的持久肠道损伤保护并增强syndecan免疫染色,乳酸林格液组持续存在器官功能障碍。
  • 肺通透性降低提示持续内皮保护;各组肾脏功能指标胱抑素C及肝脏天冬氨酸氨基转移酶和丙氨酸氨基转移酶均恢复至假手术组水平。
  • 作者认为5PRC和LPRC的可用性将允许研究冷沉淀在严重创伤患者中的即时使用,冻干产品对院前、农村和战场使用有重要意义。

适用人群与场景

  • 小鼠创伤/失血性休克模型:剖腹术后失血性休克,平均动脉压35 mmHg持续90分钟,随后6小时低血压复苏(平均动脉压55-60 mmHg),随访72小时。
  • 比较组:乳酸林格液、新鲜冰冻血浆、冷沉淀、5PRC、LPRC,并与假手术组比较。

处置流程与药物剂量

  • 小鼠创伤/失血性休克后6小时低血压复苏,目标平均动脉压55-60 mmHg,分别使用乳酸林格液、新鲜冰冻血浆、冷沉淀、5PRC或LPRC。

研究设计与关键结果

  • 研究类型:啮齿动物(小鼠)创伤/失血性休克模型实验;样本量原文未报告;比较乳酸林格液、新鲜冰冻血浆、冷沉淀、5PRC、LPRC与假手术组。
  • 基线、复苏前和按方案6小时时,实验组间平均动脉压相当。
  • 6小时内达到目标平均动脉压所需复苏液量:冷沉淀、5PRC、LPRC和新鲜冰冻血浆组均不到乳酸林格液组的一半。
  • 72小时平均动脉压:冷沉淀、5PRC和新鲜冰冻血浆组显著高于乳酸林格液组。
  • 冷沉淀、5PRC和LPRC提供与新鲜冰冻血浆相当的持久肠道损伤保护并增强syndecan免疫染色,乳酸林格液组持续存在器官功能障碍。
  • 肺通透性降低提示持续内皮保护;胱抑素C为肾脏功能指标,肝脏天冬氨酸氨基转移酶和丙氨酸氨基转移酶在所有组均恢复至假手术组水平。

证据类型、等级与局限

  • 证据类型:啮齿动物(小鼠)创伤/失血性休克模型实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,冷沉淀产品在持续性啮齿动物创伤/失血性休克及低血压复苏模型中提供与新鲜冰冻血浆相当的持久器官保护。
  • 作者认为,5PRC和LPRC的可用性将允许研究冷沉淀在严重创伤患者中的即时使用;随着冻干产品如冷沉淀在临床可用,其使用对院前、农村和战场使用有重要意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cryoprecipitate (CP) can augment hemostasis after hemorrhagic shock (HS). Similar to fresh frozen plasma (FFP), CP may provide short-term endothelial protection. We tested a new 5-day postthaw CP (5-day pathogen-reduced cryoprecipitate [5PRC]) and lyophilized pathogen-reduced cryoprecipitate (LPRC) to overcome challenges of early administration and hypothesized that 5PRC and LPRC would provide lasting organ protection in a rodent model of HS.

METHODS: Mice underwent trauma/HS (laparotomy then HS), mean arterial pressure (MAP) 35 × 90 minutes, and then 6 hours of hypotensive resuscitation (MAP, 55-60 mm Hg) with lactated Ringer's solution (LR), FFP, CP, 5PRC, or LPRC and compared with shams. Animals were followed for 72 hours. Organs and blood were collected. Data are presented as mean ± SD and analysis of variance with Bonferroni post hoc.

RESULTS: Mean arterial pressure was comparable between experimental groups at baseline, preresuscitation, and 6 hours per protocol. However, volume needed to resuscitate to target MAP over 6 hours was less than half for CP, 5PRC, LPRC, and FFP compared with LR, suggesting that CP products can serve as effective resuscitative agents. Mean arterial pressure at 72 hours was also significantly higher in the CP, 5PRC, and FFP groups compared with LR. Resuscitation with CP, 5PRC, and LPRC provided lasting protection from gut injury and enhanced syndecan immunostaining comparable with FFP, while LR mice demonstrated persistent organ dysfunction. Sustained endothelial protection was demonstrated by lessened lung permeability, while cystatin C was an indicator of kidney function, and liver aspartate aminotransferase and alanine transaminase returned to sham levels in all groups.

CONCLUSION: Cryoprecipitate products can provide lasting organ protection comparable with FFP in a sustained rodent model of trauma/HS and hypotensive resuscitation. The availability of 5PRC and LPRC will allow for investigation into the immediate use of cryoprecipitate for severely injured patients. As lyophilized products such as cryoprecipitate become available clinically, their use has important implications for prehospital, rural, and battlefield usage.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Zeineddin A, Wu F, Cao S, et al. Immediate use cryoprecipitate products provide lasting organ protection in a rodent model of trauma/hemorrhagic shock and prolonged hypotensive resuscitation. J Trauma Acute Care Surg. 2023. PMID: 37314745. doi:10.1097/TA.0000000000003981

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。